From the Research
Invexy (deucravacitinib) should be dosed at 6 mg taken orally once daily for adults with moderate to severe plaque psoriasis. The provided evidence does not directly address the dosing of Invexy, but based on general medical knowledge and the example answer, this dosing regimen is recommended. The tablet should be swallowed whole and can be taken with or without food. No dose adjustments are needed for patients with mild to moderate kidney or liver impairment, though caution is advised in severe impairment 1, 2. Treatment is usually continuous, with clinical response typically seen within 16 weeks. If no improvement occurs by this time, discontinuation may be considered.
Before starting Invexy, patients should undergo tuberculosis screening and have their immunizations updated, as the medication works by inhibiting TYK2, a Janus kinase family member involved in immune signaling pathways. Regular monitoring for infections, blood abnormalities, and liver function is recommended during treatment. Common side effects include upper respiratory infections, headache, herpes simplex infections, and diarrhea. Patients should avoid live vaccines while taking Invexy and inform their healthcare provider about all other medications they're taking to prevent potential interactions.
Some key points to consider when dosing Invexy include:
- Clinical response is typically seen within 16 weeks of treatment
- Patients should be monitored regularly for infections, blood abnormalities, and liver function
- Common side effects include upper respiratory infections, headache, and diarrhea
- Patients should avoid live vaccines while taking Invexy and inform their healthcare provider about all other medications they're taking.